Core Insights - Aimeike's stock price increased by 2.04% to 159.69 CNY per share as of November 11, with a total market capitalization of 48.32 billion CNY [1] - The company has experienced a year-to-date stock price decline of 10.04%, but a recent 5-day increase of 5.11% [1][2] - Aimeike's main business involves the research, production, and sales of biomedical soft tissue repair materials, with a revenue composition primarily from injection products [1] Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion CNY, a year-on-year decrease of 21.49%, and a net profit of 1.093 billion CNY, down 31.05% year-on-year [2] - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion CNY, with 3.012 billion CNY distributed over the past three years [3] Shareholder Information - As of October 31, 2025, Aimeike had 57,400 shareholders, an increase of 2.63% from the previous period, with an average of 3,630 circulating shares per shareholder, a decrease of 2.56% [2] - Major shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable reductions in their holdings [3]

Core Viewpoint - Fangsheng Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 22.28%, despite a slight decline in revenue for the first nine months of 2025 [1][2]. Financial Performance - As of September 30, 2025, Fangsheng Pharmaceutical reported a revenue of 1.253 billion yuan, a year-on-year decrease of 7.02%, while the net profit attributable to shareholders increased by 17.60% to 268 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Stock Market Activity - On November 11, 2025, Fangsheng Pharmaceutical's stock price rose by 2.00% to 12.24 yuan per share, with a trading volume of 39.945 million yuan and a market capitalization of 5.374 billion yuan [1]. - The stock has seen a net inflow of 326,700 yuan from major funds, with significant buying activity from large orders [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 6.50% to 31,000, while the average number of circulating shares per person increased by 6.96% to 14,167 shares [2]. - Notable changes in institutional holdings include the entry of new shareholders and increased holdings by existing ones, indicating a shift in the shareholder landscape [3].

Core Viewpoint - The stock of Ruoyuchen has experienced significant fluctuations, with a year-to-date increase of 172.40%, but a recent decline in the last 20 days by 9.77% [2] Company Overview - Ruoyuchen Technology Co., Ltd. was established on May 10, 2011, and listed on September 25, 2020. The company is based in Guangzhou, China, and its main business includes online operations, channel distribution, and brand planning [2] - The revenue composition of Ruoyuchen is as follows: 45.75% from self-owned brands, 28.83% from operational services, and 25.42% from brand management [2] - The company operates within the trade retail sector, specifically in internet e-commerce and e-commerce services, and is associated with concepts such as new retail and cosmetics [2] Financial Performance - For the period from January to September 2025, Ruoyuchen achieved a revenue of 2.138 billion yuan, representing a year-on-year growth of 85.30%. The net profit attributable to the parent company was 105 million yuan, reflecting an increase of 81.57% [2] - Since its A-share listing, Ruoyuchen has distributed a total of 245 million yuan in dividends, with 211 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Ruoyuchen was 22,800, a decrease of 16.13% from the previous period. The average number of circulating shares per person increased by 61.32% to 9,928 shares [2] - The top ten circulating shareholders include significant institutional investors, with notable increases in holdings from several funds [3]

Core Viewpoint - Water Sheep Co., Ltd. has shown significant stock performance with a year-to-date increase of 61.72%, despite recent fluctuations in trading volume and net capital outflow [1][2]. Financial Performance - For the period from January to September 2025, Water Sheep achieved a revenue of 3.409 billion yuan, representing a year-on-year growth of 11.96%. The net profit attributable to shareholders was 136 million yuan, marking a 44.01% increase [2]. - Cumulative cash dividends since the A-share listing amount to 142 million yuan, with 77.8142 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 10, 2023, Water Sheep's stock price was 21.38 yuan per share, with a market capitalization of 8.338 billion yuan. The stock experienced a 2.00% increase during the trading session [1]. - The stock has been on the龙虎榜 (top trading list) once this year, with the last appearance on May 28, where it recorded a net purchase of 24.4889 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 27,100, with an average of 13,238 circulating shares per person, a slight decrease of 0.44% [2]. - Notable changes in institutional holdings include Hong Kong Central Clearing Limited becoming the sixth-largest shareholder, increasing its stake by 5.6594 million shares [3].

Core Viewpoint - Huaxi Biological's stock price has shown a slight decline this year, with recent trading indicating a downward trend, while the company continues to maintain a diverse business model in the biotechnology sector [2][3]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms [2]. - The company has developed a full industry chain business system that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end users [2]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported operating revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - Since its A-share listing, Huaxi Biological has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed over the past three years [3]. Stock Performance - As of November 10, Huaxi Biological's stock price was 50.79 yuan per share, with a market capitalization of 24.464 billion yuan. The stock has decreased by 0.27% this year, with a 4.39% drop over the last five trading days [1][2]. - The company experienced a net inflow of main funds amounting to 2.5905 million yuan, with large orders accounting for 24.19% of total purchases [1]. Shareholder Information - As of October 31, the number of Huaxi Biological's shareholders was 30,600, an increase of 0.86% from the previous period. The average circulating shares per person decreased by 0.85% to 15,749 shares [2]. - The top ten circulating shareholders include several ETFs, with notable reductions in holdings for major funds such as E Fund and Huaxia [3].

Core Insights - The stock price of Proya increased by 2.04% on November 10, reaching 71.62 CNY per share, with a total market capitalization of 28.362 billion CNY [1] - Proya's stock has declined by 13.42% year-to-date, with a 3.01% drop over the last five trading days [1] Financial Performance - For the period from January to September 2025, Proya achieved a revenue of 7.098 billion CNY, representing a year-on-year growth of 1.89%, and a net profit attributable to shareholders of 1.026 billion CNY, up by 2.65% [2] - Cumulative cash dividends since Proya's A-share listing amount to 2.125 billion CNY, with 1.540 billion CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, Proya had 84,100 shareholders, an increase of 39.53% from the previous period, with an average of 4,708 circulating shares per shareholder, down by 28.23% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 27.1106 million shares, a decrease of 20.4089 million shares from the previous period [3]

Core Viewpoint - The stock of Pianzaihuang has shown fluctuations, with a recent increase of 2.07%, but has experienced a year-to-date decline of 15.14% [1] Group 1: Stock Performance - As of November 10, Pianzaihuang's stock price reached 179.30 yuan per share, with a total market capitalization of 108.175 billion yuan [1] - The stock has seen a net inflow of main funds amounting to 15.8065 million yuan, with significant buying and selling activities recorded [1] - Over the past 60 days, the stock has decreased by 10.22%, while it has increased by 0.66% in the last 5 trading days [1] Group 2: Financial Performance - For the period from January to September 2025, Pianzaihuang reported a revenue of 7.442 billion yuan, reflecting a year-on-year decrease of 11.93%, and a net profit of 2.129 billion yuan, down 20.74% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 8.551 billion yuan, with 4.790 billion yuan distributed in the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 130,400, with an average of 4,626 circulating shares per person, a decrease of 8.54% from the previous period [2] - Major shareholders include China Securities Finance Corporation and Hong Kong Central Clearing Limited, with notable changes in their holdings [3]

Core Viewpoint - Wan Shi Li's stock price has shown significant fluctuations, with a year-to-date increase of 18.44% and a recent 5-day increase of 13.39%, indicating strong market interest and potential growth opportunities [1][2]. Company Overview - Wan Shi Li, established on September 13, 2007, and listed on September 22, 2021, is based in Hangzhou, Zhejiang Province. The company specializes in the research, design, production, and sales of silk-related products [1]. - The main revenue sources for Wan Shi Li are silk cultural creative products (66.11%), silk textile products (31.27%), and other products (2.62%) [1]. Financial Performance - For the period from January to September 2025, Wan Shi Li reported a revenue of 519 million yuan, reflecting a year-on-year growth of 5.68%. However, the net profit attributable to shareholders decreased by 27.83% to 20.09 million yuan [2]. - Since its A-share listing, Wan Shi Li has distributed a total of 56.74 million yuan in dividends, with 43.29 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wan Shi Li decreased by 18.69% to 12,700, while the average circulating shares per person increased by 22.98% to 14,880 shares [2]. - Notably, two funds, CITIC Securities Rotation Mixed A and CITIC Securities Selected Mixed A, have exited the top ten circulating shareholders list [3]. Market Activity - On November 6, Wan Shi Li's stock rose by 2.15% to 16.17 yuan per share, with a trading volume of 87.68 million yuan and a turnover rate of 2.94%. The total market capitalization reached 3.799 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on May 9, where it recorded a net purchase of 39.21 million yuan [1].

Core Viewpoint - Shanghai Jahwa's stock price has experienced fluctuations, with a year-to-date increase of 41.13% but a recent decline in the last five and twenty trading days [1] Group 1: Stock Performance - On November 6, Shanghai Jahwa's stock fell by 2.02%, trading at 23.81 CNY per share with a total market capitalization of 16.006 billion CNY [1] - The stock has seen a net outflow of 2.7626 million CNY from main funds, with significant selling pressure in large orders [1] - Year-to-date, the stock has risen by 41.13%, but it has decreased by 3.91% in the last five trading days and 4.99% in the last twenty days [1] Group 2: Company Overview - Shanghai Jahwa, established on December 1, 1995, and listed on March 15, 2001, specializes in the research, production, and sales of skincare, personal care, and maternal and infant products [2] - The company's revenue composition includes personal care (45.70%), beauty (21.48%), overseas sales (20.20%), innovation (12.55%), and other segments [2] - As of September 30, 2025, the company reported a revenue of 4.961 billion CNY, a year-on-year increase of 10.83%, and a net profit of 405 million CNY, reflecting a significant growth of 149.12% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 21.58% to 29,600, while the average circulating shares per person increased by 27.52% to 22,704 shares [2] - The company has distributed a total of 3.595 billion CNY in dividends since its A-share listing, with 344 million CNY distributed in the last three years [3] - Hong Kong Central Clearing Limited is the second-largest circulating shareholder, increasing its holdings by 3.7706 million shares [3]

Core Viewpoint - The stock of Jia Bi You experienced a decline of 2.00% on November 4, with a current price of 23.52 CNY per share and a total market capitalization of 3.959 billion CNY [1] Financial Performance - For the period from January to September 2025, Jia Bi You achieved a revenue of 428 million CNY, representing a year-on-year growth of 10.56%. The net profit attributable to the parent company was 129 million CNY, reflecting a significant increase of 54.18% [2] - Since its A-share listing, Jia Bi You has distributed a total of 243 million CNY in dividends, with 103 million CNY distributed over the past three years [3] Stock Market Activity - As of November 4, the stock has increased by 24.91% year-to-date, but has seen declines of 2.33% over the last five trading days, 7.69% over the last twenty days, and 15.03% over the last sixty days [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on March 14, where it recorded a net purchase of 18.5019 million CNY [1] Shareholder Information - As of September 30, 2025, the number of shareholders for Jia Bi You was 8,362, an increase of 1.01% from the previous period. The average number of circulating shares per person decreased by 1.00% to 20,127 shares [2]